Written by The Ophthalmic Drugs Market is strongly influenced by the growing burden of retinal disorders. Retinal diseases accounted for approximately 32.7% of the market in 2025, supported by the prevalence of diabetic retinopathy and age-related macular degeneration. Advanced therapies, including anti-VEGF treatments and complement-pathway inhibitors, are creating new opportunities for pharmaceutical manufacturers.
The development of extended-interval treatments is another important market development. Patients receiving chronic retinal therapies may benefit from treatment approaches designed to reduce the frequency of clinical visits. Market Demand is expected to remain strong as populations age and diabetes continues to contribute to vision-threatening retinal complications.
FAQ: Which indication has a major market share?
Retinal disorders accounted for approximately 32.7% of the market in 2025.
FAQ: What is supporting retinal drug growth?
Increasing diabetic retinopathy and age-related macular degeneration, along with new therapies, are important factors.